Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 11/18/2024.
  • Additional Information
    • Alternate Title:
      Lilly-Muvalaplin
    • Subject Terms:
      Indiana
    • Abstract:
      Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study [ABSTRACT FROM PUBLISHER]